The peer-reviewed data on both the Moderna and Pfizer-BioNTech COVID vaccines are in, demonstrating 94% to 95% protection from the disease.
The phase 3 clinical trial results for the Moderna COVID-19 vaccine, mRNA-1273, and the Pfizer-BioNTech COVID-19 vaccine, BNT162b2 or Comirnaty, were published late last week in the New England Journal of Medicine (NEJM). When compared with placebos, Moderna’s vaccine showed 94.1% efficacy (95% confidence interval [CI], 89.3% to 96.8%), and Pfizer’s had 95.0% efficacy (95% CI, 90.3% to 97.6%).
Both rates are for patients who received the two intended doses. Adverse events were uncommon in both studies.
Read more at CIDRAP…